Federated Hermes, Inc. Pds Biotechnology Corp Transaction History

Federated Hermes, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	SELL	$5.68 - $11.99 $925 - $1,954	-163 Reduced 56.99%	123 $0
Q4 2022 Feb 13, 2023	SELL	$3.28 - $13.2 $2,456 - $9,886	-749 Reduced 72.37%	286 $3,000
Q3 2022 Nov 14, 2022	BUY	$2.97 - $5.79 $3,073 - $5,992	1,035 New	1,035 $3,000
Q1 2022 May 13, 2022	SELL	$4.78 - $8.43 $444 - $783	-93 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.76 - $14.35 $3,755 - $6,945	-484 Reduced 83.88%	93 $1,000
Q3 2021 Nov 15, 2021	BUY	$9.33 - $17.08 $4,375 - $8,010	469 Added 434.26%	577 $9,000
Q2 2021 Aug 16, 2021	BUY	$4.35 - $12.86 $469 - $1,388	108 New	108 $1,000
Q1 2021 May 13, 2021	SELL	$2.28 - $6.81 $875,519 - $2.62 Million	-384,000 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$0.67 - $3.04 $257,280 - $1.17 Million	384,000 New	384,000 $280,000

4.05M

253K

70.4K

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $46.1M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.